XML 52 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2

Segments of Business and Geographic Areas (Tables)

9 Months Ended

Oct. 02, 2022

Segment Reporting [Abstract]

Sales By Segment Of Business

SALES BY SEGMENT OF BUSINESS

						Fiscal Third Quarter Ended																		Fiscal Nine Months Ended
(Dollars in Millions)						October 2, 2022						October 3, 2021						Percent Change						October 2, 2022						October 3, 2021						Percent Change
CONSUMER HEALTH (1)
OTC
U.S.						$	695					686						1.4		%				$	2,028					1,960						3.5		%
International						825						798						3.4						2,434						2,223						9.5
Worldwide						1,519						1,484						2.5						4,462						4,183						6.7
Skin Health/Beauty
U.S.						591						569						3.7						1,764						1,862						(5.3)
International						535						555						(3.6)						1,500						1,595						(6.0)
Worldwide						1,126						1,124						0.1						3,264						3,457						(5.6)
Oral Care
U.S.						158						150						5.2						471						478						(1.5)
International						217						248						(12.4)						664						762						(12.8)
Worldwide						375						398						(5.8)						1,135						1,240						(8.5)
Baby Care
U.S.						91						95						(4.0)						264						288						(8.2)
International						283						296						(4.5)						840						879						(4.4)
Worldwide						375						391						(4.3)						1,105						1,167						(5.4)
Women's Health
U.S.						2						3						(22.0)						9						9						(2.8)
International						222						229						(2.7)						674						675						(0.1)
Worldwide						225						232						(3.0)						684						684						(0.1)
Wound Care/Other
U.S.						122						122						(0.2)						366						390						(6.0)
International						53						61						(11.4)						170						186						(8.2)
Worldwide						176						182						(3.9)						537						575						(6.7)
TOTAL CONSUMER HEALTH
U.S.						1,659						1,625						2.1						4,903						4,987						(1.7)
International						2,136						2,187						(2.3)						6,283						6,320						(0.6)
Worldwide						3,795						3,812						(0.4)						11,186						11,307						(1.1)

PHARMACEUTICAL(1)
Immunology
U.S.						2,876						2,771						3.8						8,230						7,932						3.8
International						1,411						1,480						(4.7)						4,587						4,464						2.8
Worldwide						4,287						4,250						0.9						12,817						12,395						3.4
REMICADE
U.S.						350						480						(27.0)						1,099						1,508						(27.1)
U.S. Exports						39						47						(16.9)						163						197						(17.2)
International						169						234						(27.8)						606						721						(16.0)
Worldwide						558						761						(26.6)						1,868						2,426						(23.0)
SIMPONI / SIMPONI ARIA
U.S.						298						295						0.9						886						840						5.4
International						248						276						(10.4)						797						877						(9.2)
Worldwide						545						571						(4.6)						1,682						1,717						(2.0)
STELARA
U.S.						1,655						1,569						5.5						4,766						4,396						8.4
International						794						809						(1.9)						2,571						2,404						6.9
Worldwide						2,449						2,378						3.0						7,336						6,800						7.9
TREMFYA
U.S.						530						376						40.7						1,303						975						33.6
International						200						161						24.6						613						459						33.7
Worldwide						729						537						35.9						1,916						1,434						33.6
OTHER IMMUNOLOGY
U.S.						5						3						*						14						15						(3.5)
International						0						0						*						0						3						*
Worldwide						5						3						*						14						18						(19.3)
Infectious Diseases
U.S.						390						679						(42.7)						1,266						1,635						(22.6)
International						905						698						29.7						2,642						1,758						50.3
Worldwide						1,295						1,378						(6.0)						3,908						3,394						15.2
COVID-19 VACCINE
U.S.						0						270						*						120						421						(71.5)
International						489						233						*						1,370						346						*
Worldwide						489						502						(2.7)						1,490						766						*
EDURANT / rilpivirine
U.S.						9						12						(27.1)						27						31						(14.5)
International						237						247						(4.2)						691						733						(5.7)
Worldwide						245						259						(5.2)						718						764						(6.1)
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.						372						380						(2.2)						1,096						1,128						(2.9)
International						112						137						(17.9)						354						440						(19.5)
Worldwide						485						517						(6.4)						1,450						1,568						(7.5)

OTHER INFECTIOUS DISEASES
U.S.						10						18						(46.4)						24						55						(57.2)
International						68						82						(17.1)						228						240						(5.0)
Worldwide						77						99						(22.4)						251						295						(14.8)
Neuroscience
U.S.						919						835						10.0						2,658						2,448						8.6
International						763						845						(9.9)						2,498						2,751						(9.2)
Worldwide						1,681						1,680						0.0						5,156						5,199						(0.8)
CONCERTA / methylphenidate
U.S.						41						35						19.3						114						117						(2.2)
International						117						122						(4.4)						362						372						(2.6)
Worldwide						158						157						0.8						476						489						(2.5)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.						684						648						5.3						2,036						1,882						8.1
International						348						355						(2.3)						1,097						1,111						(1.3)
Worldwide						1,031						1,004						2.6						3,132						2,994						4.6
RISPERDAL CONSTA
U.S.						67						71						(6.1)						195						210						(7.1)
International						52						69						(24.2)						178						242						(26.3)
Worldwide						119						140						(14.9)						373						452						(17.4)
OTHER NEUROSCIENCE
U.S.						127						81						57.2						313						239						31.1
International						246						298						(17.9)						861						1,026						(16.2)
Worldwide						374						379						(1.9)						1,174						1,265						(7.3)
Oncology
U.S.						1,812						1,525						18.8						5,073						4,364						16.2
International						2,252						2,140						5.2						6,983						6,406						9.0
Worldwide						4,064						3,665						10.9						12,056						10,770						11.9
DARZALEX
U.S.						1,097						841						30.3						3,071						2,302						33.4
International						955						739						29.3						2,823						2,076						36.0
Worldwide						2,052						1,580						29.8						5,894						4,378						34.6
ERLEADA
U.S.						254						214						19.1						693						578						20.0
International						235						130						*						647						329						*
Worldwide						490						344						42.2						1,340						907						47.7
IMBRUVICA
U.S.						353						413						(14.6)						1,072						1,311						(18.3)
International						559						654						(14.6)						1,847						1,996						(7.5)
Worldwide						911						1,066						(14.6)						2,918						3,307						(11.8)
ZYTIGA / abiraterone acetate
U.S.						16						25						(33.1)						54						96						(43.4)
International						440						523						(15.9)						1,446						1,653						(12.5)
Worldwide						456						548						(16.7)						1,500						1,749						(14.2)

OTHER ONCOLOGY
U.S.						92						32						*						183						76						*
International						64						94						(32.1)						220						352						(37.5)
Worldwide						155						126						23.1						403						428						(5.9)
Pulmonary Hypertension
U.S.						604						610						(1.1)						1,736						1,778						(2.4)
International						247						258						(3.8)						810						821						(1.3)
Worldwide						852						868						(1.9)						2,547						2,599						(2.0)
OPSUMIT
U.S.						289						299						(3.4)						827						861						(4.0)
International						152						159						(4.7)						495						510						(3.0)
Worldwide						441						458						(3.9)						1,322						1,371						(3.6)
UPTRAVI
U.S.						283						265						6.6						824						792						3.9
International						50						44						14.2						162						135						20.4
Worldwide						333						309						7.7						986						927						6.3
OTHER PULMONARY HYPERTENSION
U.S.						33						47						(29.5)						86						125						(31.3)
International						46						54						(15.7)						154						176						(13.0)
Worldwide						78						101						(22.1)						239						301						(20.5)
Cardiovascular / Metabolism / Other
U.S.						837						800						4.5						2,266						2,379						(4.8)
International						198						241						(17.5)						651						727						(10.4)
Worldwide						1,034						1,041						(0.6)						2,916						3,106						(6.1)
XARELTO
U.S.						689						636						8.4						1,806						1,794						0.7
International						—						—						—						—						—						—
Worldwide						689						636						8.4						1,806						1,794						0.7
INVOKANA / INVOKAMET
U.S.						49						66						(25.8)						164						249						(34.1)
International						60						67						(11.0)						193						194						(0.6)
Worldwide						109						133						(18.4)						357						443						(19.5)
OTHER(2)
U.S.						98						98						(0.1)						295						336						(12.2)
International						138						173						(20.0)						458						533						(14.0)
Worldwide						236						271						(12.8)						753						869						(13.3)
TOTAL PHARMACEUTICAL
U.S.						7,438						7,221						3.0						21,229						20,536						3.4
International						5,776						5,661						2.0						18,171						16,927						7.3
Worldwide						13,214						12,882						2.6						39,400						37,463						5.2

MEDTECH(3)
Interventional Solutions
U.S.						547						444						23.2						1,566						1,353						15.7
International						513						513						0.0						1,636						1,599						2.3
Worldwide						1,060						957						10.8						3,202						2,952						8.5
Orthopaedics
U.S.						1,309						1,249						4.8						3,936						3,821						3.0
International						785						843						(6.9)						2,504						2,611						(4.1)
Worldwide						2,095						2,093						0.1						6,440						6,433						0.1
HIPS
U.S.						228						209						9.1						693						651						6.5
International						124						146						(15.1)						437						451						(3.3)
Worldwide						352						355						(0.9)						1,129						1,102						2.5
KNEES
U.S.						203						184						9.8						620						579						6.9
International						115						131						(12.8)						386						403						(4.4)
Worldwide						317						316						0.4						1,005						983						2.3
TRAUMA
U.S.						473						455						3.8						1,412						1,352						4.4
International						244						260						(6.0)						749						805						(7.0)
Worldwide						717						715						0.2						2,161						2,157						0.2
SPINE, SPORTS & OTHER
U.S.						406						401						1.3						1,211						1,239						(2.2)
International						303						306						(1.1)						933						952						(2.0)
Worldwide						708						706						0.3						2,144						2,190						(2.1)
Surgery
U.S.						984						948						3.7						2,897						2,881						0.5
International						1,439						1,457						(1.2)						4,410						4,418						(0.2)
Worldwide						2,422						2,405						0.7						7,306						7,299						0.1
ADVANCED
U.S.						457						440						3.8						1,328						1,304						1.8
International						701						705						(0.4)						2,132						2,126						0.3
Worldwide						1,158						1,144						1.2						3,460						3,430						0.9
GENERAL
U.S.						527						508						3.6						1,569						1,577						(0.5)
International						737						752						(2.0)						2,277						2,292						(0.6)
Worldwide						1,264						1,261						0.3						3,846						3,869						(0.6)
Vision
U.S.						517						475						8.8						1,534						1,414						8.5
International						689						714						(3.5)						2,170						2,103						3.2
Worldwide						1,206						1,189						1.4						3,704						3,517						5.3
CONTACT LENSES / OTHER
U.S.						405						359						12.6						1,179						1,082						9.0
International						503						522						(3.6)						1,533						1,525						0.5
Worldwide						908						882						3.0						2,712						2,607						4.0

SURGICAL
U.S.						112						117						(3.2)						355						333						6.8
International						186						191						(3.3)						637						577						10.3
Worldwide						298						308						(3.2)						992						910						9.0
TOTAL MEDTECH
U.S.						3,356						3,117						7.7						9,932						9,470						4.9
International						3,426						3,527						(2.9)						10,719						10,731						(0.1)
Worldwide						6,782						6,644						2.1						20,651						20,201						2.2
WORLDWIDE
U.S.						12,453						11,963						4.1						36,064						34,993						3.1
International						11,338						11,375						(0.3)						35,173						33,978						3.5
Worldwide						$	23,791					23,338						1.9		%				$	71,237					68,971						3.3		%

*Percentage greater than 100% or not meaningful

(1) Approximately $0.1 billion in the fiscal third quarter of 2021 and $0.3 billion in the fiscal nine months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

(2) Inclusive of PROCRIT / EPREX which was previously disclosed separately

(3) Previously referred to as Medical Devices

Operating Profit by Segment of Business

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*

						Fiscal Third Quarter Ended																		Fiscal Nine Months Ended
(Dollars in Millions)						October 2, 2022						October 3, 2021						Percent Change						October 2, 2022						October 3, 2021						Percent Change
Consumer Health (1)						$	809					(577)						**						$	2,279					1,131						**
Pharmaceutical(2)						4,249						4,200						1.2						12,593						13,663						(7.8)
MedTech(3)						1,124						423						**						3,742						3,798						(1.5)
Segment earnings before provision for taxes						6,182						4,046						52.8						18,614						18,592						0.1
Less: Expense not allocated to segments (4)						111						197												471						652
Less: Consumer Health separation costs						249						—												619						—
Worldwide income before tax						$	5,822					3,849						51.3		%				$	17,524					17,940						(2.3)		%

*The 2021 fiscal third quarter and nine months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

**Percentage greater than 100% or not meaningful

(1) Consumer Health includes:

•Intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.3 billion in both the fiscal nine months of 2022 and 2021.

•Litigation expense of $0.1 billion in the fiscal nine months of 2022. Litigation expense of $1.4 billion and $1.5 billion in the fiscal three months and fiscal nine months of 2021, respectively, primarily for talc related costs.

(2) Pharmaceutical includes:

•Divestiture gains of $0.6 billion in the fiscal nine months of 2021 related to two brands outside the U.S.

•Intangible amortization expense of $0.7 billion and $0.8 billion in the fiscal third quarter of 2022 and 2021, respectively. Intangible amortization expense of $2.2 billion and $2.5 billion in the fiscal nine months of 2022 and 2021, respectively.

•In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.

•A loss of $0.2 billion and a gain of $0.1 billion related to the change in the fair value of securities in the fiscal third quarter of 2022 and 2021, respectively. A loss of $0.7 billion and a gain of $0.2 billion related to the change in the fair value of securities in the fiscal nine months of 2022 and 2021, respectively.

•COVID-19 Vaccine supply network related costs of $0.4 billion and $0.7 billion in the fiscal third quarter and fiscal nine months 2022, respectively.

•Litigation expense of $0.8 billion and $0.7 billion in the fiscal third quarter and fiscal nine months of 2021, respectively, primarily related to Risperdal Gynecomastia.

In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.5 billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.

(3) MedTech includes:

•Litigation expense of $0.2 billion in the fiscal third quarter of 2022. Litigation expense of $0.5 billion in fiscal nine months of 2022, primarily pelvic mesh related costs.

•A restructuring related charge of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.2 billion in the fiscal nine months of 2022 and 2021, respectively.

•Intangible amortization expense of $0.3 billion in both the fiscal third quarter of 2022 and 2021 and $0.8 billion in both the fiscal nine months of 2022 and 2021.

•Includes an in-process research and development expense of $0.9 billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021.

(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

SALES BY GEOGRAPHIC AREA

						Fiscal Third Quarter Ended																		Fiscal Nine Months Ended
(Dollars in Millions)						October 2, 2022						October 3, 2021						Percent Change						October 2, 2022						October 3, 2021						Percent Change
United States						$	12,453					11,963						4.1		%				$	36,064					34,993						3.1		%
Europe						5,524						5,587						(1.1)						17,633						16,669						5.8
Western Hemisphere, excluding U.S.						1,562						1,500						4.1						4,580						4,291						6.7
Asia-Pacific, Africa						4,252						4,288						(0.9)						12,960						13,018						(0.4)
Total						$	23,791					23,338						1.9		%				$	71,237					68,971						3.3		%

X

- Definition

Sales by segment of business.

+ References

No definition available.

+ Details

Name:	jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix:	jnj_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration